News

After several days of worry that the global AIDS program might come to abrupt end, Secretary of State Marco Rubio issued a humanitarian waiver that appears to have restored funding.

At today's confirmation hearing, Democratic senators were skeptical of the HHS Secretary nominee Robert F. Kennedy Jr.'s claim that he is now pro-vaccine.

Robert F. Kennedy Jr., the HHS secretary nominee, has said he is not antivaccine, but he has a track record of casting doubt on the safety and efficacy of vaccines.

In 2021 book attacking Anthony Fauci, M.D., Robert F. Kennedy Jr. casts doubt on HIV being the sole cause of AIDS and presents arguments made by "HIV deniers" that believe it is bystander in the immunosuppression that characterizes AIDS.

The survey also showed that high drug costs and artificial intelligence are topmost among the respondent’s concerns.

In this new role, Flaster will lead Cigna Healthcare’s clinical organization, focusing on initiatives to improve customer experience and deliver better health outcomes

As the nation is again under the reigns of a Trump administration and a Republican-led Congress, debates on reducing spending have not affected the public’s feelings on these programs.

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research shows.

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one prior treatment. The FDA simultaneously converted the conditional approval to full approval for this indication.

Here’s what you missed this week on Managed Healthcare Executive.

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who weigh at least 13 pounds.

Wendy Watson takes over Kaiser Foundation Health Plan and Hospitals of the Northwest, and Corwin N. Harper becomes president of Kaiser Foundation Health Plan of Georgia.

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.

TriVerity focuses on whether the patient has an infection and how severely ill they are likely to become.

Ways workplaces and insurance companies have begun to support menopausal women, according to Jenifer Allbright, Director of G&A Beneficial at G&A Partners.

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22, 2025.

First discovered in the Netherlands roughly 24 years ago, HMPV belongs to the same viral family as RSV.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.

The development of avian influenza vaccines is the main priority amid rising cases in the United States.

Health policy leaders say withdrawing from the WHO is a global health crisis in the making.

The president also promises to end the chronic disease epidemic and make two genders U.S. policy.

Datroway reduced disease progression by 37% when compared with chemotherapy.

Here’s what you missed this week on Managed Healthcare Executive.

A forecast of the year by Bill Kerr, M.D., MBA, CEO of Avalon Healthcare Solutions.

Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund, explains the biggest HIV issues anticipated this year.

Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo, Esq., HIV Project Director of the Lambda Legal Defense and Education Fund.

This ranking is based on the reviews of 12,372 consumers who evaluated their experiences with 16 major health insurance brands.

Michael Poku, M.D., chief clinical officer of Equality Health, shared his prediction for 2025.

But many existing models fall short of adhering to established best practices for economic evaluation, the review authors found. Another challenge: Existing models may not be well-suited for evaluating personalized treatments.